What is Organon's market cap?

Organon (OGN) has a market capitalization of $3.6B and trades on NYSE.

What is Organon's revenue and profitability?

Organon generated $6.2B in trailing twelve-month revenue with net income of $538.0M, representing a net margin of 8.0%. Gross margin stands at 52.8%, with free cash flow of $683.0M. These figures are based on the Q1 2026 filing.

Who are Organon's competitors?

Organon's key competitors include AbbVie, Pfizer, Amgen, and others. These companies compete in similar markets and product categories.

Who does Organon partner with?

Organon's notable partners include Samsung Bioepis, Eli Lilly, Daré Biosciences, and others.

What subsidiaries does Organon have?

Organon's subsidiaries include Dermavant Sciences Ltd., Forendo Pharma.

Where is Organon headquartered?

Organon is headquartered in United States of America and employs approximately 10,000 people. It has been publicly traded since 2021.

Organon

OGN

Organon is a global healthcare company dedicated to improving the health of women throughout their lives.

Market cap

$3.56B+36.2%

Revenue$6.2B-2.1%

Net income$538.0M-37.7%

Free cash flow$683.0M-12.1%

EPS (diluted)$2.05-38.3%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

April 30, 2026

Revenue$1.5BMiss by $27.5M EPS$0.71Miss by $0.12

Read the full report

Next report

Aug 4, 2026 (In 6 days)

Revenue estimate$1.6B

EPS estimate$0.87

Financials

Q1 2026

Income statement

See full

Revenue$1.5B-3.5%

Gross profit$783.0M-6.9%

Net income$146.0M+67.8%

EPS (diluted)$0.55+66.7%

Balance sheet

See full

Cash & equivalents$1.1B+104%

Total debt$8.6B-4.3%

Total equity$903.0M+66.6%

Total assets$13.0B-1.2%

Cash flow

See full

Operating cash flow$225.0M+200%

CapEx$37.0M+15.6%

Free cash flow$188.0M+337%

Valuation & ratios

Valuation

See full

Market cap$3.56B+36.2%

Enterprise value$11.01B+1.1%

P/E6.6×—

P/S0.6×+0.2×

Profitability

See full

Gross margin52.8%-4.4pp

FCF margin11.1%-1.3pp

Returns & leverage

See full

Debt / equity9.5×-7.0×

Current ratio2×+0.3×

Segments

By product

See full

Nexplanon/Implanon NXT$201.0M-19.0%

Other$87.0M+11.5%

Zetia$87.0M+2.4%

Atozet$85.0M+10.4%

Other Non-Opiod Pain, Bone and Dermatology$68.0M0.0%

By geography

See full

Europe and Canada$412.0M+9.6%

Latin America, Middle East, Russia, and Africa$247.0M+2.9%

Asia Pacific and Japan$226.0M-10.0%

Other$23.0M-23.3%

Competitors

By market cap

Organon$3.6B+37.2%

Opko Health$936.3M-12.5%

Vanda Pharmaceuticals$313.9M+13.3%

SCN

Scienture Holdings, Inc.$14.9M-43.4%

By revenue growth

Organon-2.1%

By net margin

Organon7.95%-5.0pp

Opko Health-12.4%+14.3pp

Profile

Organon is a global healthcare company dedicated to improving the health of women throughout their lives. The company maintains a diverse portfolio of over 70 products, including contraception, fertility treatments, biosimilars, and established brands across multiple therapeutic areas. Organon leverages a significant international footprint to deliver essential medicines and innovative health solutions to more than 140 countries and territories.

Competitive position

A leading global provider of women's health solutions with a dominant position in long-acting reversible contraception and a significant portfolio of established legacy brands.

GeographiesUnited States, China, European Union, Canada, Brazil, Mexico, Australia

Customer segmentsWholesalers, Healthcare Providers, Government Agencies, Pharmacy Benefit Managers

Business modelManufacturing, Research and Development, Licensing and Distribution

SuppliersRaw material suppliers, Active pharmaceutical ingredient (API) manufacturers, Contract manufacturing organizations, Biopharmaceutical R&D partners

CustomersDrug wholesalers, Retail pharmacies, Hospitals and clinics, Government health ministries, Managed care organizations

CountryUnited States of America

Listed2021

Employees10.0K

CEOJoseph T. Morrissey Jr.

SectorHealthcare

IndustryDrug Manufacturers - General

Websiteorganon.com

FilingsSEC EDGAR

Ask your AI about Organon.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Organon's market cap?: Organon (OGN) has a market capitalization of $3.6B and trades on NYSE.
What is Organon's revenue and profitability?: Organon generated $6.2B in trailing twelve-month revenue with net income of $538.0M, representing a net margin of 8.0%. Gross margin stands at 52.8%, with free cash flow of $683.0M. These figures are based on the Q1 2026 filing.
Who are Organon's competitors?: Organon's key competitors include AbbVie, Pfizer, Amgen, and others. These companies compete in similar markets and product categories.
Who does Organon partner with?: Organon's notable partners include Samsung Bioepis, Eli Lilly, Daré Biosciences, and others.
What subsidiaries does Organon have?: Organon's subsidiaries include Dermavant Sciences Ltd., Forendo Pharma.
Where is Organon headquartered?: Organon is headquartered in United States of America and employs approximately 10,000 people. It has been publicly traded since 2021.